To celebrate together the FH Awareness Day, we would like to invite you to a special webinar with our esteemed expert speakers on Friday September 24th at 5:30 CET. This year, we wish to discuss with you how the latest developments in Familial Hypercholesterolaemia serve as an evidence-based model of innovation in CVD and its prevention.
Register now to secure your space. Alternatively, watch live on Facebook here.
Cardiovascular diseases (CVD) account for one third of global deaths and are the main cause of mortality worldwide. In low- and middle-income countries, 80% of the deaths are associated with CVD. The World Health Organization aims to reduce premature mortality due to non-communicable diseases by at least 30% by 2030.
The diseases that cause the greatest global burden, such as the CVD, are multifactorial. It is estimated that up to 75% of premature CVD is preventable. Traditional CVD management is largely aimed at changing lifestyle-related factors. However, advances in genomic medicine allow for a more comprehensive approach: accurate diagnosis, improvement in risk stratification and targeted treatment. The value of precision medicine is defined by all the data that can be generated about an individual. Advances go beyond isolated clinical data, imaging or classical laboratory tests, toward the integration of more complex data sets (genomics, metabolomics, proteomics and so on), sometimes called “panomic profiling”. The applications of genomics and emerging sciences have the potential to revolutionize the prevention, diagnosis and treatment of cardiovascular diseases, following the model that already revolutionized oncology. Personalized medicine refers to the implementation of such data in a patient-specific plan using biomarkers.
Classic approaches in contemporary cardiology cannot yet explain why, for example, myocardial infarction also occurs in young people or why a person with an apparently “healthy” lifestyle is at very high cardiovascular risk.
|